Ингаляционный тобрамицин в лечении хронической синегнойной инфекции при муковисцидозе


https://doi.org/10.18093/0869-0189-2013-0-4-109-114

Полный текст:


Аннотация

Ингаляционный тобрамицин в лечении хронической синегнойной инфекции при муковисцидозе.


Об авторах

Е. Л. Амелина
ФГБУ "НИИ пульмонологии" ФМБА России
Россия

к. м. н., зав. лабораторией муковисцидоза 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-53-84.



С. А. Красовский
ФГБУ "НИИ пульмонологии" ФМБА России
Россия

к. м. н., научный сотрудник лаборатории муковисцидоза 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-74-15.



Список литературы

1. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004; 23: 146–158.

2. Høiby N., Krogh Johansen H., Moser C. et al. Pseudomonas aeruginosaand the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001; 3: 23–35.

3. Armstrong D.S., Grimwood K., Carzino R. et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br. Med. J. 1995; 310: 1571–1572.

4. Armstrong D.S., Hook S.M., Jamsen K.M. et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmon. 2005; 40: 500–510.

5. Hansen C.R., Pressler T., Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 2008; 7: 523–530.

6. Cooney G.F., Lum B.L., Tomaselli M., Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 1994; 34: 255–259.

7. Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226.

8. Jelsbak L., Johansen H.K., Frost A.L. et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. and Immun. 2007; 75: 2214–2224.

9. Ramsey B.W., Dorkin H.L., Eisenberg J.D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1993; 328: 1740–1746.

10. Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs 2007; 9: 11–20.

11. Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658–664.

12. Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23–30.

13. Chuchalin A., Gyurkovics K., Bartnicka M.T. et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr. Drugs 2007; 9: 21–31.

14. Geller D.E., Konstan M.W., Smith J. et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmon. 2007; 42: 307–313.

15. Konstan M.W., Flume P.A., Keppler M. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011; 10 (1): 54–61.

16. Konstan M., Geller D.E., Minic P. et al. Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr. Pulmon. 2011; 46: 230–238.

17. Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120: 107S–113S.

18. Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.

19. AHFS drug information 2006. Tobramycin sulfate. http://www.ashp.org/ahfs/first-rel/Revised3tobramycinoct2006.pdf [accessed 1 Nov 2007].

20. Kerem E., Reisman J., Corey M. et al. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 1992; 326: 1187–1191.

21. Ramsey B.W., Boat T.F. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J. Pediatr. 1994; 124: 177–192.

22. Iles R., Legh3Smith J., Drummond M. et al. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J. Cyst. Fibros. 2003; 2: 120–128.

23. Anderson G.G., Moreau3Marquis S., Stanton B.A., O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. and Immun. 2008; 76: 1423–1433.

24. Murphy T.D., Anbar R.D., Lester L.A. et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. 2004; 38: 314–320.

25. Mazurek H., Chiron R., Varoli G. et al. Efficacy on lung function and safety of multiple courses of tobramycin 300 mg / 4 ml nebuliser solution (Bramitob®) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: Results from a 48-week extension phase. In: Poster presented on 35th ECFS Conference, Dublin, Ireland, June 2012.

26. Govoni M., Poli G., Cicirello H. et al. Pharmacokinetics of tobramycin nebulizer solution 300 mg / 4 ml (Bramitob®) administered by Pari eFlow® Rapid vs Pari LC® Plus nebulizer in cystic fibrosis patients. Pulmon. Pharmacol. Ther. 2013; 26 (2): 249–255.

27. Engel T., Heinig J.H., Madsen F., Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler®). Eur. Respir. J. 1990; 3: 1037–1041. Online Resources.

28. Tiddens H.A., Geller D.E., Challoner P. et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol. Med. 2006; 19 (4): 456–465.


Дополнительные файлы

Для цитирования: Амелина Е.Л., Красовский С.А. Ингаляционный тобрамицин в лечении хронической синегнойной инфекции при муковисцидозе.  Пульмонология. 2013;(4):109-114. https://doi.org/10.18093/0869-0189-2013-0-4-109-114

For citation: Amelina E.L., Krasovsky S.A. Tobramycin inhalations in therapy of chronic infection Pseudomonas aeruginosa in cystic fibrosis. Russian Pulmonology. 2013;(4):109-114. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-4-109-114

Просмотров: 265

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)